Larger trials with detailed analysis of excised tissues will be required to dissect the mechanistic underpinnings of the beneficial effects of anakinra for endometriosis, but a clear window of opportunity exists for the control of the pervasive pathologic inflammation in this disease.[72] Convergence of evidence highlighting IL1A/B as a central hub of pro‐inflammatory signaling in endometriosis, together with promising early clinical data[59] supports continued investigation of IL1R therapy for endometriosis, where new non‐hormonal therapeutic options are urgently needed. The gene discussed is IL1A; the disease is endometriosis.